At Techsol Life Sciences, we take pride to be a trusted partner for pharma, biotech and medical device companies to help them navigate through the complex clinical development process and successfully bring their medical products faster to market. As a regional India-based CRO, we have a team of highly experienced professionals who have a proven-track record of working across different therapeutic areas for early phase to late phase clinical studies. We use advanced technology and leverge data-driven decision making to generate high-quality scientific outcomes that accounts for the quality, safety, efficacy and performance of your medical products.
We work closely with our clients to develop a deep understanding of their needs and goals, and we strive to exceed their expectations in every aspect of our service delivery. Our commitment to quality and customer satisfaction has helped us build long-term relationships with our clients, and we are proud of the reputation we have earned in the industry.
With our 20+ years of combined team experience, sponsors have entrusted us as a reliable CRO partner because of our unwavering focus on patient safety, regulatory compliance and data quality. With our domain expertise, we have a well-established clinical operations team for managing the conduct of pre-clinical studies to post-marketing surveillance.
Techsol's Clinical PIVOT Framework
Our team has a track record of successfully engaging with over 40+ sponsors using our proprietary Clinical PIVOT Framework that is powered by having connected teams, processes, and technology. It has six important core components that are fully leveraged to accelerate clinical development and deliver maximum value for sponsors.
Our capabilities in early phase clinical studies include conducting first-in-human studies, dose-escalation studies, and proof-of-concept studies. Our team has experience in conducting randomized, double-blind, adaptive trial design, and placebo-controlled studies primarily in oncology, CNS, cardiovascular, and infectious diseases both in healthy volunteers and patient populations.
Our capabilities in late-phase clinical studies is centered around Phase III trials and RWE data collection for post-marketing surveillance.
Request More Information
Contact us today to learn more about our capabilities and how we can help you with your next clinical research project.